| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary target of Mogroside VI B is the transcriptional coactivator PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). Mogroside VI B shows an effect on activating PGC-1α transcription. By modulating PGC-1α activity, the compound may influence various metabolic processes, including mitochondrial biogenesis, glucose and lipid metabolism, and thermogenesis. This makes it a valuable tool for studying metabolic disorders such as obesity and diabetes.
|
|---|---|
| ln Vitro |
Mogroside VI B exhibits mild impacts on the activity of the PGC-1α promoter. Mogroside VI B has the ability to stimulate PGC-1α at a concentration of 20 μM[1].
In vitro, Mogroside VI B has been shown to activate PGC-1α transcription. This activity was identified in studies using reporter gene assays. The compound's ability to modulate PGC-1α expression makes it a useful tool for studying the regulation of energy metabolism at the molecular level. |
| ln Vivo |
In vivo, Mogroside VI B may have potential metabolic effects through its activation of PGC-1α transcription. By upregulating PGC-1α, the compound could enhance mitochondrial function and energy expenditure. However, detailed in vivo efficacy data are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro assays for Mogroside VI B typically involve cell-based reporter gene assays to measure PGC-1α promoter activity. Cells are transfected with a reporter construct containing the PGC-1α promoter and treated with the compound. The activation of the promoter is measured by quantifying the reporter signal.
|
| Cell Assay |
In vitro cellular assays for Mogroside VI B may involve the use of cell lines to study its effects on PGC-1α expression and downstream metabolic pathways. Cells are treated with the compound, and the expression of PGC-1α and its target genes is measured by qPCR or Western blotting.
|
| Animal Protocol |
In vivo animal studies for Mogroside VI B are not detailed in the available literature. As a research tool, it could be administered to rodent models of metabolic disease to assess its effects on energy metabolism, insulin sensitivity, and body weight.
|
| ADME/Pharmacokinetics |
Mogroside VI B has a molecular formula of C66H112O34 and a molecular weight of 1449.59. It is a solid with a density of 1.55±0.1 g/cm3 (predicted). It is typically stored under standard conditions. Detailed pharmacokinetic parameters are not available.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for Mogroside VI B. As a research chemical, it should be handled with standard safety precautions.
|
| References | |
| Additional Infomation |
Mogroside VI B is a cucurbitane glucoside isolated from Siraitia grosvenorii (Luo Han Guo). It has a molecular formula of C66H112O34 and a molecular weight of 1449.59. It shows an effect on activating PGC-1α transcription.
|
| Molecular Formula |
C66H112O34
|
|---|---|
| Molecular Weight |
1449.57510566711
|
| Exact Mass |
1446.724
|
| CAS # |
2149606-17-5
|
| Appearance |
White to off-white solid powder
|
| LogP |
-4.5
|
| SMILES |
C[C@]12C3CC[C@H](O[C@@H]4O[C@H](CO[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C(C3=CC[C@H]1[C@@]1(C)[C@@](C)([C@H](CC1)[C@@H](CC[C@@H](O[C@H]1[C@H](O[C@H]3[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O1)C(C)(C)O)C)C[C@H]2O)(C)C
|
| InChi Key |
FRSXWRODNFMFEO-BSIITDIOSA-N
|
| InChi Code |
InChI=1S/C67H114O33/c1-25(27-15-16-65(6)37-13-11-28-29(67(37,8)38(72)18-66(27,65)7)12-14-39(63(28,2)3)98-60-54(87)49(82)44(77)36(97-60)24-91-59-53(86)47(80)41(74)32(20-69)94-59)9-10-26(64(4,5)89)17-30-56(50(83)45(78)35(92-30)23-90-58-52(85)46(79)40(73)31(19-68)93-58)99-62-57(51(84)43(76)34(22-71)96-62)100-61-55(88)48(81)42(75)33(21-70)95-61/h11,25-27,29-62,68-89H,9-10,12-24H2,1-8H3/t25-,26+,27?,29?,30+,31+,32-,33-,34+,35-,36-,37?,38-,39+,40+,41-,42-,43+,44-,45-,46-,47+,48+,49+,50+,51-,52+,53-,54-,55-,56+,57+,58+,59-,60+,61+,62-,65+,66-,67+/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2S,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(2R,5S)-5-[(3R,9S,11S,13S,14R)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-[[(2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-(2-hydroxypropan-2-yl)hexyl]oxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6899 mL | 3.4493 mL | 6.8985 mL | |
| 5 mM | 0.1380 mL | 0.6899 mL | 1.3797 mL | |
| 10 mM | 0.0690 mL | 0.3449 mL | 0.6899 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
